Oxidative stress and psychological disorders

Samina Salim, Samina Salim

Abstract

Oxidative stress is an imbalance between cellular production of reactive oxygen species and the counteracting antioxidant mechanisms. The brain with its high oxygen consumption and a lipid-rich environment is considered highly susceptible to oxidative stress or redox imbalances. Therefore, the fact that oxidative stress is implicated in several mental disorders including depression, anxiety disorders, schizophrenia and bipolar disorder, is not surprising. Although several elegant studies have established a link between oxidative stress and psychiatric disorders, the causal relationship between oxidative stress and psychiatric diseases is not fully determined. Another critical aspect that needs much attention and effort is our understanding of the association between cellular oxidative stress and emotional stress. This review examines some of the recent discoveries that link oxidative status with anxiety, depression, schizophrenia and bipolar disorder. A discussion of published results and questions that currently exist in the field regarding a causal relationship between oxidative and emotional stress is also provided.

Keywords: Psychological stress; anxiety; depression.; oxidative stress.

References

    1. Selye H. The Evolution of the Stress Concept. 1973;61(6):692–699.
    1. Gingrich JA. Oxidative stress is the new stress. In: Nat Med: United States. 2005;11pp:1281–1282.
    1. Irie M, Asami S, Ikeda M, Kasai H. Depressive state relates to female oxidative DNA damage via neutrophil activation. Biochem. Biophys Res. Commun. 2003;311(4):1014–1018 .
    1. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM. Accelerated telomere shortening in response to life stress. Proc. Natl. Acad. Sci. U. S. A. 2004;101(49):17312–17315.
    1. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom. Med. 2006;68(1):1–7.
    1. Gidron Y, Russ K, Tissarchondou H, Warner J. The relation between psychological factors and DNA-damage: a critical review. Biol. Psychol. 2006;72(3):291–304.
    1. Pero RW, Roush GC, Markowitz MM, Miller DG. Oxidative stress, DNA repair, and cancer susceptibility. Cancer Detect.rev. . 1990;14(5):555–561.
    1. Halliwell B. Biochemistry of oxidative stress. Biochem. Soc. Trans. 2007;35(Pt 5):1147–1150.
    1. Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem. Soc. Symp. 1995;61:1–31.
    1. Berg D, Youdim MB, Riederer P. Redox imbalance. Cell Tissue Res. 2004;318(1):201–213.
    1. Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol. 2002;30(6):620–650.
    1. Halliwell B. Phagocyte-derived reactive species: salvation or suicide?. Trends Biochem. Sci. 2006;31(9):509–515.
    1. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007;39(1):44–84.
    1. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 2000;20(10):2175–2183.
    1. Konat GW. H2O2-induced higher order chromatin degradation: a novel mechanism of oxidative genotoxicity. J. Biosci. 2003;28(1):57–60.
    1. Lockwood TD. Redox control of protein degradation. Antioxid. Redox Signal. 2000;2(4):851–878.
    1. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids. 2003;25(3-4):207–218.
    1. Horton AA, Fairhurst S. Lipid peroxidation and mechanisms of toxicity. Crit. Rev. Toxicol. 1987;18(1):27–79.
    1. Raha S, Robinson BH. Mitochondria, oxygen free radicals, and apoptosis. Am. J. Med. Genet. 2001;106(1):62–70.
    1. Aksenova MV, Aksenov MY, Mactutus CF, Booze RM. Cell culture models of oxidative stress and injury in the central nervous system. Curr. Neurovasc. Res. 2005;2(1):73–89.
    1. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci. 2008;29(7):346–351.
    1. Filomeni G, Ciriolo MR. Redox control of apoptosis: an update. Antioxid. Redox Signal. 2006;8(11-12):2187–2192.
    1. Halliwell B. Reactive species and antioxidants.Redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006;141(2):312–322.
    1. Greco T, Fiskum G. Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J. Alzheimers Dis. 2010;20(Suppl 2 ):S427–437.
    1. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 2001;7(3):115–121.
    1. Reynolds A, Laurie C, Mosley RL, Gendelman HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol. 2007;82:297–325.
    1. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008;11(6):851–876.
    1. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid. Med. Cell Longev. 2009;2(2):63–67.
    1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence severity and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry. 2005;62(6):617–627.
    1. McCord JM, Fridovich I. Superoxide dismutase: the first twenty years (1968-1988). Free Radic. Biol. Med. 1988;5(5-6):363–369.
    1. Chelikani P, Fita I, Loewen PC. Diversity of structures and properties among catalases. Cell Mol. Life Sci. 2004;61(2):192–208.
    1. Krohne-Ehrich G, Schirmer RH, Untucht-Grau R. Glutathione reductase from human erythrocytes.Isolation of the enzyme and sequence analysis of the redox-active peptide. Eur. J. Biochem. 1977;80(1):65–71.
    1. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004;114(12):1752–1761.
    1. Poulsen HE, Specht E, Broedbaek K, Henriksen T, Ellervik C, Mandrup-Poulsen T, Tonnesen M, Nielsen PE, Andersen HU, Weimann A. RNA modifications by oxidation: a novel disease mechanism?. Free Radic Biol Med. 2012;52(8):1353–1361.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 2000
    1. Hovatta I, Tennant RS, Helton R, Marr RA, Singer O, Redwine JM, Ellison JA, Schadt EE, Verma IM, Lockhart DJ, Barlow C. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature. 2005;438(7068):662–666.
    1. Masood A, Nadeem A, Mustafa SJ, O'Donnell JM. Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. J. Pharmacol. Exp. Ther. 2008;326(2):369–379.
    1. Souza CG, Moreira JD, Siqueira IR, Pereira AG, Rieger DK, Souza DO, Souza TM, Portela LV, Perry ML. Highly palatable diet consumption increases protein oxidation in rat frontal cortex and anxiety-like behavior. Life Sci. 2007;81(3):198–203.
    1. Bouayed J, Rammal H, Younos C, Soulimani R. Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice. Eur. J. Pharmacol. 2007;564(1-3):146–149.
    1. de Oliveira MR, Silvestrin RB, Mello EST, Moreira JC. Oxidative stress in the hippocampus, anxiety-like behavior and decreased locomotory and exploratory activity of adult rats: effects of sub acute vitamin A supplementation at therapeutic doses. Neurotoxicology. 2007;28(6):1191–1199.
    1. Salim S, Asghar M, Chugh G, Taneja M, Xia Z, Saha K. Oxidative stress: a potential recipe for anxiety, hypertension and insulin resistance. Brain Res. 2010;1359:178–185.
    1. Salim S, Sarraj N, Taneja M, Saha K, Tejada-Simon MV, Chugh G. Moderate treadmill exercise prevents oxidative stress-induced anxiety-like behavior in rats. Behav. Brain Res. 2010;208(2):545–552.
    1. Salim S, Asghar M, Taneja M, Hovatta I, Wu YL, Saha K, Sarraj N, Hite B. Novel role of RGS2 in regulation of antioxidant homeostasis in neuronal cells. FEBS Lett. 2011;585(9):1375–1381.
    1. Vollert C, Zagaar M, Hovatta I, Taneja M, Vu A, Dao A, Levine A, Alkadhi K, Salim S. Exercise prevents sleep deprivation-associated anxiety-like behavior in rats: potential role of oxidative stress mechanisms. Behav Brain Res. 2011;224(2):233–240.
    1. Salim S, Asghar M, Taneja M, Hovatta I, Chugh G, Vollert C, Vu A. Potential contribution of oxidative stress and inflammation to anxiety and hypertension. Brain Res. 2011;1404:63–71.
    1. Patki G, Allam FH, Atrooz F, Dao AT, Solanki N, Chugh G, Asghar M, Jafri F, Bohat R, Alkadhi KA, Salim S. Grape powder intake prevents ovariectomy-induced anxiety-like behavior, memory impairment and high blood pressure in female wistar rats. PLoS One. 2013;8(9):e74522.
    1. Chugh G, Asghar M, Patki G, Bohat R, Jafri F, Allam F, Dao AT, Mowrey C, Alkadhi K, Salim S. A high-salt diet further impairs age-associated declines in cognitive, behavioral, and cardiovascular functions in male Fischer brown norway rats. J. Nutr. 2013;143(9):1406–1413.
    1. Allam F, Dao AT, Chugh G, Bohat R, Jafri F, Patki G, Mowrey C, Asghar M, Alkadhi KA, Salim S. Grape powder supplementation prevents oxidative stress-induced anxiety-like behavior, memory impairment, and high blood pressure in rats. J. Nutr. 2013;143(6):835–842.
    1. Patki G, Solanki N, Atrooz F, Allam F, Salim S. Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res. 2013
    1. Klann E, Thiels E. Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1999;23(3):359–376.
    1. Serrano F, Klann E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res. Rev. 2004;3(4):431–443.
    1. Ailing F, Fan L, Li S, Manji S. Role of extracellular signal-regulated kinase signal transduction pathway in anxiety. J Psychiatr. Res. 2008;43(1):55–63.
    1. Mazzucchelli C, Brambilla R. Ras-related and MAPK signalling in neuronal plasticity and memory formation. Cell Mol. Life Sci. 2000;57(4):604–611.
    1. Qi X, Lin W, Li J, Pan Y, Wang W. The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behav. Brain Res. 2006;175(2):233–240.
    1. Reul JM, Chandramohan Y. Epigenetic mechanisms in stress-related memory formation. Psychoneuroendocrinology. 2007;32(Suppl 1 ):S21–25.
    1. Shin JA, Lee KE, Kim HS, Park EM. Acute Resveratrol Treatment Modulates Multiple Signaling Pathways in the Ischemic Brain. Neurochem. Res. 2012
    1. Yousuf S, Atif F, Ahmad M, Hoda N, Ishrat T, Khan B, Islam F. Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia. Brain Res. 2009;1250:242–253.
    1. Gard PR. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin. Ther. Targets. 2004;8(1):7–14.
    1. Sorce S, Krause KH. NOX enzymes in the central nervous system: from signaling to disease. Antioxid. Redox Signal. 2009;11(10):2481–2504.
    1. Inaba S, Iwai M, Furuno M, Tomono Y, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension. 2009;53(2):356–362.
    1. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ, Goncalves CA, Young LT, Yatham LN. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263–271.
    1. Tsaluchidu S, Cocchi M, Tonello L, Puri BK. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry. 2008;8(Suppl 1 ):S5.
    1. Yumru M, Savas HA, Kalenderoglu A, Bulut M, Celik H, Erel O. Oxidative imbalance in bipolar disorder subtypes: a comparative study. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009;33(6):1070–1074.
    1. Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem. Res. 2010;35(9):1295–1301.
    1. Nair D, Dayyat EA, Zhang SX, Wang Y, Gozal D. Intermittent hypoxia-induced cognitive deficits are mediated by NADPH oxidase activity in a murine model of sleep apnea. PLoS One. 2011;6(5):e19847.
    1. Schiavone S, Sorce S, Dubois-Dauphin M, Jaquet V, Colaianna M, Zotti M, Cuomo V, Trabace L, Krause KH. Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry. 2009;66(4):384–392.
    1. Kessler RC. The effects of stressful life events on depression. Annu. Rev. Psychol. 1997;48:191–214.
    1. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry. 1992;149(8):999–1010.
    1. Belmaker RH, Agam G. Major depressive disorder. N. Engl. J. Med. 2008;358(1):55–68.
    1. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011;35(3):676–692.
    1. Maes M. An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011;35(3):784–794.
    1. Suzuki H, Colasanti M. NO: a molecule with two masks of 'NO' theatre. Biofactors. 2001;15(2-4):123–125.
    1. Dhir A, Kulkarni SK. Nitric oxide and major depression. Nitric Oxide. 2011;24(3):125–131.
    1. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 2011;14(1):123–130.
    1. Lee SY, Lee SJ, Han C, Patkar AA, Masand PS, Pae CU. Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2013;46:224–235.
    1. Pae CU, Yu HS, Kim TS, Lee CU, Lee SJ, Jun TY, Lee C, Serretti A, Paik IH. Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res. 2004;127(3):279–281.
    1. Pae CU, Marks DM, Han C, Patkar AA, Steffens D. Does neurotropin-3 have a therapeutic implication in major depression?. . Int. J .Neurosci. 2008;118(11):1515–1522.
    1. Behr GA, Moreira JC, Frey BN. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid. Med. Cell Longev. 2012;2012:609421.
    1. Chung CP, Schmidt D, Stein CM, Morrow JD, Salomon RM. Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatry Res. 2013;206(2-3):213–216.
    1. Hoffer A, Osmond H, Smythies J. Schizophrenia a new approach.II. Result of a year's research. J. Ment. Sci. 1954;100(418):29–45.
    1. Pandya CD, Howell KR, Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog. Neuro- psychopharmacol. Biol. Psychiatry. 2013;46:214–223.
    1. Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int. J. Neuropsychopharmacol. 2010;13(2):257–271.
    1. Boskovic M, Vovk T, Kores Plesnicar B, Grabnar I. Oxidative stress in schizophrenia. Curr. Neuropharmacol. 2011;9(2):301–312.
    1. Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush AI. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci. Lett. 2011;499(3):149–153.
    1. Gama CS, Salvador M, Andreazza AC, Kapczinski F, Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuro- psychopharmacol Biol Psychiatry. 2006;30(3):512–515.
    1. Herken H, Uz E, Ozyurt H, Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. In: Schizophr. Res. Netherlands. 2001;52 pp:289–290.
    1. Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol. Psychiatry. 1991;30(4):409–412.
    1. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum. Psychopharmacol. 2007;22(2):67–73.
    1. Wu JQ, Kosten TR, Zhang XY. Free radicals antioxidant defense systems, and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2013;46:200–206.
    1. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res. 1998;32(6):385–391.
    1. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J. Clin. Psychiatry. 2007;68(5):754–760.
    1. Kunz M, Gama CS, Andreazza AC, Salvador M, Cereser KM, Gomes FA, Belmonte-de-Abreu PS, Berk M, Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32(7):1677–1681.
    1. Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr. Res. 1996;19(1):19–26.
    1. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. Decreased antioxidant enzymes and membrane essential poly- unsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121(2):109–122.
    1. Altuntas I, Aksoy H, Coskun I, Caykoylu A, Akcay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin. Chem. Lab Med. 2000;38(12):1277–1281.
    1. Stoklasova A, Zapletalek M, Kudrnova K, Randova Z. Glutathione peroxidase activity in the blood in chronic schizophrenia. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl. 1986;29(1-2):103–108.
    1. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin. Chem. 1986;32(5):805–807.
    1. Golse B, Debray-Ritzen P, Puget K, Michelson AM. Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses. Nouv Presse Med. 1977;6(27):2449.
    1. Yao JK, Reddy RD, van Kammen DP. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol. Psychiatry. 1999;45(11):1512–1515.
    1. Shinkai T, De Luca V, Zai G, Shaikh S, Matsumoto C, Arnold PD, Hwang R, King N, Trakalo J, Potapova N, Wong G, Hori H, Wong AH, Ohmori O, Nakamura J, Kennedy JL. No association between the Pro197Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia. Psychiatr. Genet. 2004;14(3):177–180.
    1. Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol. Psychiatry. 1987;22(11):1349–1356.
    1. Buckman TD, Kling A, Sutphin MS, Steinberg A, Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res. 1990;31(1):1–14.
    1. Yao JK, Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid. Redox Signal. 2011;15(7):1999–2002.
    1. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J. Neurosci. 2008;28(51):13957–13966.
    1. Bruce-Keller AJ, Gupta S, Parrino TE, Knight AG, Ebenezer PJ, Weidner AM, LeVine H, 3rd; Keller JN, Markesbery WR. NOX activity is increased in mild cognitive impairment. Antioxid. Redox Signal. 2010;12(12):1371–1382.
    1. Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr. Opin. Neurobiol. 2009;19(2):220–230.
    1. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, Wu D, Xue R, Andrade M, Tankou S, Mori S, Gallagher M, Ishizuka K, Pletnikov M, Kida S, Sawa A. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl. Acad. Sci. U. S. A. 2007;104(36):14501–14506.
    1. Johnson AW, Jaaro-Peled H, Shahani N, Sedlak TW, Zoubovsky S, Burruss D, Emiliani F, Sawa A, Gallagher M. Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness. Proc. Natl. Acad. Sci. U. S. A. 2013;110(30):12462–12467.
    1. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN. Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord. 2008;111(2-3):135–144.
    1. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V, Jr., da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 2007;421(1):33–36.
    1. Savas HA, Gergerlioglu HS, Armutcu F, Herken H, Yilmaz HR, Kocoglu E, Selek S, Tutkun H, Zoroglu SS, Akyol O. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J. Biol. Psychiatry. 2006;7(1):51–55.
    1. Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev. Bras. Psiquiatr. 2011;33(4):374–378.
    1. Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord. 2011;13(5-6):454–465.
    1. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J. Affect. Disord. 2011;135(1-3):389–394.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다